Abstract: Described herein are probes useful to detect gene copy number alterations of genes characteristic/indicative of cutaneous T cell lymphoma (CTCL), such as CTCL with blood involvement, including probes specific to genes amplified or deleted in cutaneous T cell lymphoma (CTCL), such as CTCL with blood involvement; methods of detecting a (one or more) genetic abnormality, such as one or more gene copy number alteration (GCNA), characteristic/indicative of cutaneous T cell lymphoma (CTCL), such as CTCL with blood involvement, in a biological sample obtained from an individual; and methods of determining if an individual has cutaneous T cell lymphoma (CTCL), such as CTCL with blood involvement, or is likely to develop cutaneous T cell lymphoma (CTCL) with blood involvement.

Abstract: The present invention relates to a device and method for determining the presence of a specific compound in solution. The device includes a nanosensor having an electrically conducting pathway between at least a first and second contact. The device also includes a first receptor, suitable for binding a specific compound in the solution, attached to the nanosensor, and a second receptor also suitable for binding the specific compound while the specific compound is bound to the first receptor. The second receptor is attached to an enzyme added to the solution. When the solution having the second receptor is added to the device, and a second compound that is a substrate for the enzyme is subsequently added to the solution, a measured difference in an electrical property in the device before and after the application of the second compound is indicative of the presence of the specific compound in the solution.

Abstract: The invention includes a method of preventing or treating a fibrotic lung disease in a subject, comprising administering to the subject a thyroid hormone by inhalation and/or aerosolization. The invention further comprises compositions and kits comprising compositions useful within the invention.

Abstract: The present invention includes compositions and methods for treating disease and disorders associated with pathological calcification or pathological ossification by modulating the level or activity of NPP1 or a mutant thereof, or a mutant NPP4 modified to exhibit ATP hydrolase activity similar to the hydrolase activity of NPP1.

Abstract: According to some aspects, a quantum mechanical system is provided, comprising a resonator having a plurality of superconducting surfaces and configured to support at least one electromagnetic oscillation mode within a three-dimensional region, wherein the plurality of superconducting surfaces include a first superconducting surface that defines a first plane, and a physical qubit comprising at least one planar component that is planar within the first plane and borders the three-dimensional region.

Abstract: An isolated transport peptide, which crosses the cell membrane of a cell and/or binds to a target cell, is described. The transport peptide can be incorporated into a transport construct in which the transport peptide is linked to a cargo moiety to be delivered into a cell. Also described herein is a method of delivering a transport construct into and/or to a cell.

Abstract: Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease. The genetically modified non-human animals comprise a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter. In some instances, the genetically modified non-human animal expressing human IL-6 also expresses at least one of human M-CSF, human IL-3, human GM-CSF, human SIRPa or human TPO. In some instances, the genetically modified non-human animal is immunodeficient. In some such instances, the genetically modified non-human animal is engrafted with healthy or diseased human hematopoietic cells. Also provided are methods for using the subject genetically modified non-human animals in modeling human hematopoietic cell development, function, and/or disease, as well as reagents and kits thereof that find use in making the subject genetically modified non-human animals and/or practicing the subject methods.

Abstract: According to some aspects, a quantum circuit is provided including a plurality of non-linear circuit elements coupled together in series and in parallel, such that at least two of the circuit elements are coupled together in series and at least two of the circuit elements are coupled together in parallel, wherein the quantum circuit is configured to act as an amplifier.

Abstract: Polyamine-co-ester-co-ortho ester) polymers, methods of forming active agent-load nanoparticles therefrom, and methods of using the nanoparticles for drug delivery are disclosed. The nanoparticles can be coated with an agent that reduces surface charge, an agent that increases cell-specific targeting, or a combination thereof. Typically, the loaded nanoparticles are less toxic, more efficient at drug delivery, or a combination thereof compared to a control or other transfection reagents.

Abstract: A very low pressure gas or blow forming process for shaping a bulk metallic glass (BMG) in its supercooled liquid state that avoids the frictional stick forces experienced by conventional shaping techniques by engineering the expansion of a pre-shape or parison of BMG material such that substantially all of the lateral strain required to form the final article is accomplished prior to the outer surface of the parison contacting the surface of the shaping apparatus is provided. The capability offered by the inventive shaping process to avoid the frictional forces exerted by the shaping apparatus surface allows for the formation of precision net-shape complex multi-scale parts and components using processing conditions inaccessible by conventional processes.

Abstract: Disclosed herein is a species of peptide and non-peptide inhibitors of Akt, an oncogenic protein. Beginning with a residue of Akt target substrate GSK-3, the functional domains of the GSK-3 residue were characterized. Functionally homologous non-peptide groups were substituted for the amino acids of the GSK-3 creating a hybrid peptide-non-peptide and non-peptide compounds capable of binding to Akt. The non-peptide compounds show increased stability and rigidity compared to peptide counterparts and are less susceptible to degradation. The bound non-peptide compounds exhibit an inhibitory effect on Akt, similar to peptide-based Akt inhibitors.

Abstract: According to some aspects, a circuit is provided comprising a plurality of Josephson junctions arranged in series in a loop, at least one magnetic element producing magnetic flux through the loop, a plurality of superconducting resonators, each resonator coupled to the loop between a different neighboring pair of Josephson junctions of the plurality of Josephson junctions, a plurality of ports, each port coupled to at least one of the plurality of resonators at ends of the resonators opposite to ends at which the resonators are coupled to the loop, and at least one controller configured to provide input energy to each of the plurality of ports that causes the circuit to function as a circulator between the plurality of ports.

Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.

Abstract: Some aspects are directed to a method of operating an apparatus, the apparatus comprising a first quantum system having a plurality of coherent quantum states, the first quantum system being coupled to a second quantum system, the method comprising providing an input energy signal to the second quantum system that stimulates energy transfer between the first quantum system and the second quantum system and that causes net dissipation of energy to be output from the second quantum system, wherein the input energy signal includes at least two components having different frequencies and each having an amplitude and a phase, and adiabatically varying the amplitude and the phase of the at least two components of the input energy signal to cause a change in one or more of the plurality of coherent quantum states of the first quantum system.

Abstract: The present invention relates to compositions and methods for modulating coagulation through modulating the level or activity of NPP4.

Abstract: Methods for increasing the patency of biodegradable, synthetic vascular grafts are provided. The methods include administering one or more cytokines and/or chemokines that promote outward tissue remodeling of the vascular grafts and vascular neotissue formation. The disclosed methods do not require cell seeding of the vascular grafts, thus avoiding many problems associated with cell seeding. Biodegradable, polymeric vascular grafts which provide controlled release of cytokines and/or chemokines at the site of vascular graft implantation are also provided.

Abstract: The present invention relates to predictors of a cancer patient's responsiveness to immunotherapy for cancer.

Abstract: Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.

Abstract: The present invention relates to identification of a human gene, DCDC2 (MIM: 605755), associated with susceptibility for developing reading disability (RD), which is useful in identifying or aiding in identifying individuals at risk for developing RD, as well as for diagnosing or aiding in the diagnosis of RD.

Abstract: The invention provides a method of treatment comprising reducing therapy-induced adverse effects (TIAE), including chemotherapy-induced adverse effects (CIAE), such as chemotherapy-induced peripheral neuropathy (CIPN) and/or chemotherapy-induced cardiovascular adverse effects (CICAE) in a subject being treated with a CIAE-inducing anti-cancer active ingredient by co-administering to the subject a pharmaceutically effective amount of a NCS-1-protective composition. Related pharmaceutical compositions, diagnostics and screening techniques are also provided.